Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2009

01.09.2009 | Laboratory Investigation - Human/Animal Tissue

Genetically engineered T cells to target EGFRvIII expressing glioblastoma

verfasst von: Szofia S. Bullain, Ayguen Sahin, Oszkar Szentirmai, Carlos Sanchez, Ning Lin, Elizabeth Baratta, Peter Waterman, Ralph Weissleder, Richard C. Mulligan, Bob S. Carter

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Glioblastoma remains a significant therapeutic challenge, warranting further investigation of novel therapies. We describe an immunotherapeutic strategy to treat glioblastoma based on adoptive transfer of genetically modified T-lymphocytes (T cells) redirected to kill EGFRvIII expressing gliomas. We constructed a chimeric immune receptor (CIR) specific to EGFRvIII, (MR1-ζ). After in vitro selection and expansion, MR1-ζ genetically modified primary human T-cells specifically recognized EGFRvIII-positive tumor cells as demonstrated by IFN-γ secretion and efficient tumor lysis compared to control CIRs defective in EGFRvIII binding (MRB-ζ) or signaling (MR1-delζ). MR1-ζ expressing T cells also inhibited EGFRvIII-positive tumor growth in vivo in a xenografted mouse model. Successful targeting of EGFRvIII-positive tumors via adoptive transfer of genetically modified T cells may represent a new immunotherapy strategy with great potential for clinical applications.
Literatur
1.
2.
Zurück zum Zitat Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH et al (2003) Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9(11):4247–4254PubMed Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH et al (2003) Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9(11):4247–4254PubMed
3.
Zurück zum Zitat Ochiai H, Archer GE, Herndon JEII, Kuan CT, Mitchell DA, Bigner DD et al (2008) EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8 + T cells. Cancer Immunol Immunother 57(1):115–121. doi:10.1007/s00262-007-0363-7 PubMedCrossRef Ochiai H, Archer GE, Herndon JEII, Kuan CT, Mitchell DA, Bigner DD et al (2008) EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8 + T cells. Cancer Immunol Immunother 57(1):115–121. doi:10.​1007/​s00262-007-0363-7 PubMedCrossRef
4.
8.
Zurück zum Zitat Kawasaki H, Becker ML, Hedrick SM (1991) Specificity for molecules of the major histocompatibility complex mediated by a hybrid immunoglobulin-T cell receptor. New Biol 3(5):487–497PubMed Kawasaki H, Becker ML, Hedrick SM (1991) Specificity for molecules of the major histocompatibility complex mediated by a hybrid immunoglobulin-T cell receptor. New Biol 3(5):487–497PubMed
9.
Zurück zum Zitat Roberts MR, Qin L, Zhang D, Smith DH, Tran AC, Dull TJ et al (1994) Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 84(9):2878–2889PubMed Roberts MR, Qin L, Zhang D, Smith DH, Tran AC, Dull TJ et al (1994) Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 84(9):2878–2889PubMed
11.
Zurück zum Zitat Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I (1996) Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 93(25):14815–14820. doi:10.1073/pnas.93.25.14815 PubMedCrossRef Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I (1996) Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 93(25):14815–14820. doi:10.​1073/​pnas.​93.​25.​14815 PubMedCrossRef
12.
Zurück zum Zitat Beers R, Chowdhury P, Bigner D, Pastan I (2000) Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res 6(7):2835–2843PubMed Beers R, Chowdhury P, Bigner D, Pastan I (2000) Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res 6(7):2835–2843PubMed
13.
Zurück zum Zitat Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC (2002) Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA 99(10):7009–7014. doi:10.1073/pnas.092562399 PubMedCrossRef Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC (2002) Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA 99(10):7009–7014. doi:10.​1073/​pnas.​092562399 PubMedCrossRef
14.
Zurück zum Zitat Lupton SD, Brunton LL, Kalberg VA, Overell RW (1991) Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol Cell Biol 11(6):3374–3378PubMed Lupton SD, Brunton LL, Kalberg VA, Overell RW (1991) Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol Cell Biol 11(6):3374–3378PubMed
15.
Zurück zum Zitat Murphy GJ, Mostoslavsky G, Kotton DN, Mulligan RC (2006) Exogenous control of mammalian gene expression via modulation of translational termination. Nat Med 12(9):1093–1099. doi:10.1038/nm1376 PubMedCrossRef Murphy GJ, Mostoslavsky G, Kotton DN, Mulligan RC (2006) Exogenous control of mammalian gene expression via modulation of translational termination. Nat Med 12(9):1093–1099. doi:10.​1038/​nm1376 PubMedCrossRef
16.
Zurück zum Zitat Szentirmai O, Baker CH, Lin N, Szucs S, Takahashi M, Kiryu S et al (2006) Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 58(2):365–372 (discussion-72)PubMedCrossRef Szentirmai O, Baker CH, Lin N, Szucs S, Takahashi M, Kiryu S et al (2006) Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 58(2):365–372 (discussion-72)PubMedCrossRef
17.
Zurück zum Zitat Brocker T (2000) Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96(5):1999–2001PubMed Brocker T (2000) Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96(5):1999–2001PubMed
18.
20.
22.
Zurück zum Zitat Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N et al (2006) CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66(22):10995–11004. doi:10.1158/0008-5472.CAN-06-0160 PubMedCrossRef Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N et al (2006) CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66(22):10995–11004. doi:10.​1158/​0008-5472.​CAN-06-0160 PubMedCrossRef
23.
Zurück zum Zitat Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG et al (2007) Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 18(8):712–725. doi:10.1089/hum.2007.028 PubMedCrossRef Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG et al (2007) Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 18(8):712–725. doi:10.​1089/​hum.​2007.​028 PubMedCrossRef
24.
Zurück zum Zitat Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK (2006) Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20(10):1819–1828. doi:10.1038/sj.leu.2404366 PubMedCrossRef Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK (2006) Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20(10):1819–1828. doi:10.​1038/​sj.​leu.​2404366 PubMedCrossRef
25.
Zurück zum Zitat Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 20(1):70–75. doi:10.1038/nbt0102-70 PubMedCrossRef Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 20(1):70–75. doi:10.​1038/​nbt0102-70 PubMedCrossRef
26.
Zurück zum Zitat Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC (2004) Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64(24):9160–9166. doi:10.1158/0008-5472.CAN-04-0454 PubMedCrossRef Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC (2004) Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64(24):9160–9166. doi:10.​1158/​0008-5472.​CAN-04-0454 PubMedCrossRef
28.
Zurück zum Zitat Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE et al (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66(6):3294–3302. doi:10.1158/0008-5472.CAN-05-3773 PubMedCrossRef Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE et al (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66(6):3294–3302. doi:10.​1158/​0008-5472.​CAN-05-3773 PubMedCrossRef
30.
Zurück zum Zitat Jiang HR, Gilham DE, Mulryan K, Kirillova N, Hawkins RE, Stern PL (2006) Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J Immunol 177(7):4288–4298PubMed Jiang HR, Gilham DE, Mulryan K, Kirillova N, Hawkins RE, Stern PL (2006) Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J Immunol 177(7):4288–4298PubMed
Metadaten
Titel
Genetically engineered T cells to target EGFRvIII expressing glioblastoma
verfasst von
Szofia S. Bullain
Ayguen Sahin
Oszkar Szentirmai
Carlos Sanchez
Ning Lin
Elizabeth Baratta
Peter Waterman
Ralph Weissleder
Richard C. Mulligan
Bob S. Carter
Publikationsdatum
01.09.2009
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2009
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-009-9889-1

Weitere Artikel der Ausgabe 3/2009

Journal of Neuro-Oncology 3/2009 Zur Ausgabe

Laboratory Investigation - Human/Animal Tissue

Pineal gland tumors: experience from the SEER database

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.